# A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

> **NCT03530683** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 189 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma
- Acute Myeloid Leukemia
- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Maplirpacept (PF-07901801)
- **DRUG:** Azacitidine
- **DRUG:** Venetoclax
- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Anti-CD20 Targeting agent
- **DRUG:** Isatuximab

## Key facts

- **NCT ID:** NCT03530683
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-14
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 189 (ACTUAL)
- **Why stopped:** A business decision was made by Pfizer to terminate the study. Termination was not due to any safety concerns, requests from regulatory authorities, changes to the benefit/risk profile or any new concerns regarding the investigational product.
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03530683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03530683, "A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03530683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*